BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $545 thousand, or $0.05 per basic and diluted common share, compared to a net loss of $(1.05) million, or $(0.09) per basic and diluted
Related Questions
How does the $0.05 EPS from continuing operations compare to analyst consensus estimates?
What were the total revenues and how do they compare to the same quarter last year?
What drove the swing from a $1.05 million loss to a $545 k profit?
What is the company's cash and cash equivalents balance after Q2?
Did TherapeuticsMD provide any guidance for Q3 or full‑year 2025 earnings?
What are the projected royalty income streams for the next 12‑18 months?
Are there any upcoming royalty or licensing agreements that could affect future cash flows?
How does the net margin for the quarter compare to prior quarters and industry peers?
What are the key risks highlighted in the MD&A that could impact future earnings?
How does the current valuation (P/E, EV/EBITDA) compare to other royalty‑focused pharma companies?
What is the company's debt level and any upcoming maturities?
Did the company announce any share buyback or dividend plans?
What is the impact of the results on the stock’s technical indicators (e.g., moving averages, RSI)?
Are there any pending regulatory or legal matters that could affect the company’s cash flow?
How does the earnings per share compare on a diluted basis versus basic?
What is the outlook for the company's key royalty assets (e.g., patent expirations, new product launches)?
How does the net income from continuing operations compare to net income from discontinued operations?
Is there any indication of a potential acquisition or partnership in the pipeline?
What is the expected impact of macro‑economic trends on the company’s royalty revenue?
What is the company's guidance on capital expenditures for the remainder of 2025?